The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
S | Sensory organs | |
2
|
S01 | Ophthalmologicals | |
3
|
S01L | Ocular vascular disorder agents | |
4
|
S01LA | Antineovascularisation agents | |
5
|
S01LA06 |
| Active Ingredient |
|---|
|
Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment with a molecular weight of ~26 kDa. Brolucizumab binds with high affinity to VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, brolucizumab suppresses endothelial cell proliferation, thereby reducing pathological neovascularisation and decreasing vascular permeability. |
| Document | Type | Information Source | |
|---|---|---|---|
| BEOVU Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| BEOVU Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.